Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 17/20 | 0.90 |
| ▸ | S1PR4 | O95977 | 12/20 | 0.90 |
| ▸ | S1PR5 | Q9H228 | 12/20 | 0.90 |
| ▸ | S1PR3 | Q99500 | 9/20 | 0.53 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3173252 | 1.00 | S1PR1 (0.90) | S1PR1S1PR4S1PR5S1PR3SPHK2 | |
| SCHEMBL3169901 | 0.95 | S1PR1 (0.87) | S1PR1S1PR4S1PR5S1PR3 | |
| SCHEMBL3169863 | 0.95 | S1PR1 (0.87) | S1PR1S1PR4S1PR5S1PR3 | |
| SCHEMBL13527440 | 0.95 | S1PR1 (0.87) | S1PR1S1PR4S1PR5S1PR3 | |
| SCHEMBL2956978 | 0.95 | S1PR1 (1.00) | S1PR1S1PR4S1PR5S1PR3 | |
| SCHEMBL2953362 | 0.95 | S1PR1 (1.00) | S1PR1S1PR4S1PR5S1PR3 | |
| SCHEMBL13237728 | 0.95 | S1PR1 (1.00) | S1PR1S1PR4S1PR5S1PR3 | |
| SCHEMBL2953369 | 0.95 | S1PR1 (1.00) | S1PR1S1PR4S1PR5S1PR3 | |
| SCHEMBL2956971 | 0.95 | S1PR1 (1.00) | S1PR1S1PR4S1PR5S1PR3 | |
| SCHEMBL13527543 | 0.94 | S1PR1 (0.89) | S1PR1S1PR4S1PR5S1PR3SPHK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016260-A1 | AGONISTS OF SPHINGOSINE-1 PHOSPHATE RECEPTOR (SLP) | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2010-01-21 | — | — | US | claimed |
| US-20080070866-A1 | Chemical compounds | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-03-20 | — | — | US | claimed |
| US-20100016260-A1 | AGONISTS OF SPHINGOSINE-1 PHOSPHATE RECEPTOR (SLP) | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2010-01-21 | — | — | US | disclosed |
| US-20080070866-A1 | Chemical compounds | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016260-A1 | AGONISTS OF SPHINGOSINE-1 PHOSPHATE RECEPTOR (SLP) | S1PR1, S1PR2, S1PR5 | S1PR1 1/4885S1PR4 5/4885S1PR5 3/4885 |
| US-20080070866-A1 | Chemical compounds | S1PR1, S1PR2, S1PR5 | S1PR1 1/4885S1PR4 5/4885S1PR5 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.